---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-019006"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:34:00.129437+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Biofrontera closes purchase of Ameluz/RhodoLED US assets, reduces earnout to 12-15%

## Summary
- Acquired all U.S. assets and rights to Ameluz and RhodoLED, including NDA, patents, manufacturing, and personnel.
- New earnout structure: 12% of net sales up to $65M, 15% above; replaces prior 25-35% perpetual payment.
- Closing released final $2.5M of $11M financing led by existing investors Rosalind Advisors and AIGH.
- Biofrontera AG receives 10% post-money equity stake in Biofrontera Inc., aligning long-term interests.
- Company expects full asset and personnel transfer by late Q4 2025 or early Q1 2026.

## SEC filing metadata
- accession: 0001493152-25-019006
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315225019006/0001493152-25-019006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315225019006/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-019006
- JSON: https://secwatch.observer/filing/0001493152-25-019006.json
- Plain text: https://secwatch.observer/filing/0001493152-25-019006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.